Innovative Therapies to Treat and Cure HDV and Other Serious Diseases



April 2022

Forward Looking Statements

This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements include words such as "believe," "will," "may," "estimate," "continue," "anticipate," "contemplate," "intend," "target," "project," "should," "plan," "expect," "predict," "could," "potentially," other words of similar meaning and the negative of these terms. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, timing for and outcomes of clinical results, prospective products, preclinical and clinical pipelines, regulatory objectives, business strategy and plans and objectives for future operations, are forward looking statements. Forward-looking statements are our current statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our anticipated significant milestones in 2022; the timing of our ongoing and planned clinical development; the sufficiency of our cash, cash equivalents and investments to fund our operations into the third quarter of 2023; the expectations regarding the timing and availability of topline data in our Phase 3 D-LIVR study in HDV; the continued screening of patients and activation of clinical trial sites in our LIMT-2 study; the potential approval of Zokinvy[®] in jurisdictions outside of the U.S., including the EU; our ability to maintain supply of our commercial and clinical trial materials; our plans to advance Peginterferon Lambda in HDV in the U.S. and EU; our progression of Peginterferon Lambda for COVID-19 and Avexitide for post-bariatric hypoglycemia and congenital hyperinsulinism; our ability to finance the continued advancement of our development pipeline products; and the potential for success of any of our product candidates. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Eiger makes, including additional applicable risks and uncertainties described in the "Risk Factors" sections in the Annual Report on Form 10-K for the year ended December 31, 2021 and Eiger's subsequent filings with the SEC. The forward-looking statements contained in this press release are based on information currently available to Eiger and speak only as of the date on which they are made. Eiger does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise. Additional information may be available in press releases or other public announcements and public filings made after the date of this presentation.

© 2022 Eiger Biopharmaceuticals, Inc., all rights reserved. All trademarks belong to their respective owners.



Advancing Pipeline for HDV and Other Serious Diseases

Indication	Product Candidate	Phase 2	Phase 3	Marketed
Hepatitis Delta Virus	Lonafarnib			
	Peginterferon Lambda			
COVID-19	Peginterferon Lambda			
Congenital Hyperinsulinism				
Post-Bariatric Hypoglycemia	Avexitide			
Progeria	Cokinvy® (lonafarnib) capsules 50 mg/75 mg			



HDV: A Deadly Global Disease

TREATMENTS DESPERATELY NEEDED


>12M Patients globally

50%

of patients are cirrhotic at the time of diagnosis

Eiger HDV Platform


FIRST IN CLASS TREATMENTS IN DEVELOPMENT FOR HDV





HDV: Always a Co-infection with HBV


HDV REQUIRES HBsAg TO COMPLETE VIRUS ASSEMBLY





HDV: Most Severe Form of Viral Hepatitis

50% OF PATIENTS CIRRHOTIC AT DIAGNOSIS






HDV Treatments Are Needed

HBV THERAPIES IN DEVELOPMENT DO NOT ERADICATE HDV

- HDV requires only small amounts of HBsAg to complete viral packaging
- Approved HBV NUCs only suppress HBV DNA, do not affect HBsAg, and have no impact on HDV
- Theoretically, only a sterilizing HBV cure could obviate a need for an HDV cure
- Sterilizing HBV cure Aspirational, at best
- Functional HBV cure Not yet; combinations need to first be identified


HDV Therapies On Track for Approval Years Ahead of an HBV Functional Cure








Different Mechanisms of Action to Treat HDV





Eiger Developing Complementary Treatments for HDV



Eiger HDV Platform in Phase 3

FIRST IN CLASS TREATMENTS IN DEVELOPMENT FOR HDV

Lonafarnib

- Only oral agent in development
- 2,000+ patients dosed in ONC program
- 450+ patients dosed in HDV program
- Orphan Designation in U.S. and EU
- FDA Breakthrough Therapy Designation
- Patent protection through late-2030s

Peginterferon Lambda

- Well-tolerated interferon
- 3,000+ patients dosed in HCV / HBV
- 50+ patients dosed in HDV program
- Orphan Designation in U.S. and EU
- FDA Breakthrough Therapy Designation
- 12 years biologics exclusivity



What Does a Win Look Like for HDV Patients?

CONSISTENT WITH FDA GUIDANCE ON DEVELOPMENT OF TREATMENTS FOR HDV*

- Reduction in HDV Viral Load
 - Improvement in Liver Inflammation (ALT)


- Slows Disease Progression
- Improves Liver Histology
- Improves Survival





Lonafarnib Phase 2 Program: 129 HDV Patients Dosed

TWO LONAFARNIB-BASED REGIMENS IDENTIFIED FOR REGISTRATION











MULTIPLE PATHWAYS TO APPROVAL



* biopsy

All patients will be maintained on background HBV nucleoside therapy. Superiority over PEG IFN-alfa-2a not required.










Topline Data Planned by End of 2022








Peginterferon Lambda for HDV

A WELL TOLERATED INTERFERON





Physician Perspectives on Lambda vs. Alfa

>90% PREFERENCE FOR LAMBDA CONTAINING THERAPIES

From a tolerability standpoint, I can say that Lambda is a completely different ballgame compared to Alfa. If there were a treatment option as good as Alfa in terms of efficacy, nobody would use Alfa anymore.

"

If I can get the same efficacy with Lambda that I get with Alfa, I would prescribe Lambda over Alfa.

Most of the patients I treated with Lambda were previously treated with Alfa. But when we started the medication, patients pointed out that **this is a completely different experience compared to Alfa**.

77

66

I can say without hesitation that all patients I treated with Lambda had either minimal or no side effects whatsoever in terms of their patient experience.

"




77



Phase 2 Peginterferon Lambda Study Results


36% DURABLE VIROLOGIC RESPONSE (DVR) WITH PEGINTERFERON LAMBDA





Regression of Liver Fibrosis Following 48 Weeks of Lambda in HDV


BIOPSIES FROM PRE- AND POST-LIMT LAMBDA MONOTHERAPY STUDY







LVMT-2 Peginterferon Lambda Phase 3 Study of HDV ACTIVATING SITES AND ENROLLING PATIENTS



*Primary Endpoint: DVR (Arm 1) versus HDV RNA BLQ After 12 Weeks No TRx (Arm 2)

DVR (Durable Virologic Response) = Below the Limit of Quantification (BLQ) at 24 Weeks Post-Treatment





$\mathbf{V} = \mathbf{W} - \mathbf{Z}$ Phase 3 Global Study

OVERLAP WITH D-LIVR SITES; POISED FOR EFFICIENT ENROLLMENT





Accelerated Approval Paths for Lonafarnib & Peginterferon Lambda

Phase 3 *D-LIVR* (Lonafarnib) Study for CHRONIC Therapy




FDA Guidance – CHRONIC, ON-TRx Endpoint:

"...≥ 2 log decline in HDV RNA and ALT normalization on-treatment could be considered an acceptable surrogate endpoint..."




Phase 3 LIMT-2 (Peginterferon Lambda) Study for FINITE Therapy (Cure)



Eiger HDV Platform

FIRST IN CLASS TREATMENTS IN DEVELOPMENT FOR HDV








LIFT – 1 Peginterferon Lambda + Lonafarnib Combo


TREATMENT FOR 24 WEEKS







LIFT – 2 Peginterferon Lambda + Lonafarnib Combo TREATMENT FOR 48 WEEKS






\$1B+ HDV Market Opportunity

ONLY 3% MARKET PENETRATION REQUIRED



Concentrated U.S. Prescriber Base: Targeted Field Promotion


70% OF U.S. HBV RX WRITTEN BY ~3,500 OR 10% OF TOTAL PRESCRIBERS






Commercial Launch Strategy

>\$1B COMMERCIAL OPPORTUNITY IN U.S., EUROPE, AND CHINA





Foundational Therapies to Treat and Cure HDV





COVID-19: An Evolving Pandemic

MORE TREATMENTS NEEDED

~450M

Cases to date globally

~6.1M Deaths to date globally

March 17, 2022



Eiger's Single-dose Peginterferon Lambda for COVID-19 Reduced Risk of Hospitalization or ER Visits by 50% in a Predominantly Vaccinated Population in Phase 3 *TOGETHER* Study

- Second largest study to date in COVID-19 outpatients (N=1,936)
- Highly superior compared to placebo, with a probability of superiority of 99.91% on the primary endpoint
- 60% reduced risk of COVID-19-related death
- Primary endpoint achieved across multiple SARS-CoV-2 variants, including omicron
- Eiger plans to submit data to FDA for Emergency Use Authorization (EUA)




VIEWPOINT

COVID-19 and emerging viral infections: The case for interferon Lambda

Prokunina-Olsson et al J. Exp. Med. April **2020** Vol. 217 No. 5





- Type III IFNs: First line of defense upon infection of airways
- Lambda IFN produced first to limit virus spread at epithelial barrier without triggering inflammation



together • COVID-19 Phase 3 Study SECOND LARGEST TREATMENT STUDY IN COVID-19

- Multi-center, investigator-sponsored, randomized, placebo-controlled Phase 3 study in Brazil (12 sites)
- Single injection of Peginterferon Lambda vs. Placebo
- Randomized within 7 days of symptom onset and positive SARS-CoV-2 test
- Enrolled 1,936 high-risk, non-hospitalized, 84% vaccinated patients from Jul 2021 Feb 2022
- High-risk criteria defined by patients having at least one of the following criteria, including but not limited to:
 > age 50, diabetes, hypertension, CV disease, lung disease, kidney disease, obesity, etc.
- Primary endpoint is reduction of COVID-19 related hospitalizations or emergency room visits through Day 28



Lambda Highly Superior Compared to Placebo


<u>99.91% PROBABILITY OF SUPERIORITY</u>, SURPASSING PRESPECIFIED SUPERIORITY THRESHOLD OF 97.6%

Risk	Lambda n=916	Placebo n=1020 Reduction (95% BCI)		Probability of Superiority*
Hospitalizations or ER visits	25 (2.7%)	57 (5.6%)	50% (23 - 69%)	99.9%
Hospitalizations	21 (2.3%)	41 (4%)	42% (5 - 66%)	98.4%

- 1 death in Lambda group; 4 deaths in Placebo group
- 84% patients were vaccinated

35


 Incidence of any adverse event was indistinguishable between Lambda and Placebo group





Lambda Highly Superior Compared to Placebo

NON-OVERLAPPING CONFIDENCE INTERVALS



Statistical analysis conducted in a Bayesian framework Prespecified Threshold of Superiority = 97.6%

36



together • COVID-19 Phase 3 Study

REPRESENTATIVE OF CURRENT, REAL-WORLD COVID-19 POPULATION

Risk	# Days of Symptoms Before Treatment	Risk Reduction (95% BCI)	Probability of Superiority*	
Hospitalizations or ER visits	≤ 7 days	50% (23 - 69%)	99.9%	
	≤ 3 days	67% (19 - 79%)	99.6%	
Hospitalizations	≤ 7 days	39% (1 – 64%)	97.7%	
or Deaths	≤ 3 days	60% (17 – 82%)	99.4%	

- Superior efficacy in a predominantly vaccinated population
- 60% reduction in hospitalizations or death with early treatment
- Pan-variant efficacy in variants tested, including omicron
- Potential for efficacy to new arising variants

Demonstrated risk reduction in COVID-19-related hospitalizations or deaths in a predominantly vaccinated population; NO OTHER INVESTIGATIONAL DRUG HAS ACHIEVED THIS



Peginterferon Lambda for COVID-19

POTENTIAL AS A CONVENIENT, OUTPATIENT THERAPY FOR NEWLY DIAGNOSED PATIENTS


- 300,000 doses of Lambda by end of 2022
- Plan to scale up manufacturing for additional doses
- Positive results facilitate discussions with potential partners including government, non-government and pharma





Peginterferon Lambda for COVID-19

POTENTIAL "ONE AND DONE" TREATMENT FOR NEWLY DIAGNOSED COVID-19 OUTPATIENTS



In-clinic IV infusion

Potential for viral resistance



Rare Diseases: Urgent Medical Needs

BREAKTRHOUGH THERAPY PROGRAMS

Avexitide


Congenital Hyperinsulinism Post Bariatric Hypoglycemia

Zokínvy[®] (lonafarnib) capsules 50 mg/75 mg FDA Approved for Progeria

Avexitide: First-in-Class GLP-1 Antagonist

TARGETED MOA FOR POST-BARIATRIC HYPOGLYCEMIA AND CONGENITAL HYPERINSULINISM

- 31 Amino Acid Fragment of Exenatide, a GLP-1 Agonist
- Novel Liquid Formulation Developed
- Sub-cutaneous Delivery
- Targeted Mechanism of Action
- Differential Market Strategies for PBH & HI
- Patent Protection Will Provide Market Exclusivity Through at Least 2039





Avexitide for HI and PBH

PHASE 3 READY 2022

CONGENITAL HYPERINSULINISM (HI) Regulatory Discussions Ongoing for Phase 3



- Ultra-rare pediatric metabolic disorder
- Most frequent cause of persistent hypoglycemia in neonates and children
- Occurs in **1:25,000** to **1:50,000** live births
- FDA Breakthrough Therapy Designation
- FDA Rare Pediatric Disease Designation

POST-BARIATRIC HYPOGLYCEMIA (PBH) Single Phase 3 Study Agreed with FDA & EMA



- Complication of bariatric surgery
- Dangerously low blood sugar after meals
- ~5-10% of Roux-en-Y Gastric Bypass
- ~2.5% of Vertical Sleeve Gastrectomy
- FDA Breakthrough Therapy Designation

HI results in **PERMANENT BRAIN DAMAGE** with neurodevelopmental deficits in up to 50% of patients

PBH results in SEVERE HYPOGLYCEMIA: altered mental status, loss of consciousness, seizures, coma




Zokínvy[®] FDA Approved to Reduce the Risk of Mortality in Hutchinson-Gilford Progeria Syndrome (Progeria)







Photos courtesy of The Progeria Research Foundation and Progeria Family Circle







Launched in January 2021 in U.S.



80% of Identified Patients Converted to Commercial Supply

EIGERONE CARE.



Dedicated and Disease State Specialized Team Focused on Needs of Patients and Practices



Reimbursement and Copay Assistance and Patient Assistance Programs




Direct Link to the Pharmacy for Seamless Access

Scalable Distribution & Patient Services for Future Launches





Planning for Launch in Europe in 2022





- Distribution and patient support services provider selected for launch
- Reimbursed early access program approved in France
- Completed first shipment in Q4 2021



Advancing Pipeline for HDV and Other Serious Diseases

Indication	Product Candidate	Phase 2	Phase 3	Marketed
Hepatitis Delta Virus	Lonafarnib		2	
	Peginterferon Lambda	LVMT-2		
COVID-19	Peginterferon Lambda		COVID-19	
Congenital Hyperinsulinism	Averitida			
Post-Bariatric Hypoglycemia	Avexitide			
Progeria	Cokinvy [®] (lonafarnib) capsules 50 mg/75 mg			



A Pivotal Moment for Eiger

Delivering Needed Wins for HDV Patients

- Phase 3 *D*-*LIVR* Lonafarnib data by end of 2022
- Phase 3 LIMT-2 Lambda study enrolling
- Phase 2 *LIFT-2* combination study initiating

Potential for "One-and-Done" Therapy for COVID-19

- Positive Phase 3 TOGETHER results
- Lambda highly superior to placebo in hospitalizations or ER visits
- Plan to discuss data with FDA and submit EUA

Five Breakthrough Therapy Designated Orphan Programs

- HDV (Lonafarnib and Lambda)
- Congenital Hyperinsulinism
- Post-Bariatric Hypoglycemia
- Progeria